Palisade Bio completes patient selection strategies for patients with UC

Palisade Bio announced the successful completion of refined patient selection strategies based on PDE4-related biomarkers and disease characteristics to optimize clinical outcomes for patients with UC as part of its collaboration with Strand Life Sciences. As part of the ongoing collaboration with Strand, RNAseq datasets were analyzed using a standardized bioinformatics pipeline, which generates normalized TPM counts for each gene. The analysis found that PDE4B expression is significantly higher in most colitis patients, encompassing both adult and pediatric cohorts. This suggests that PDE4B could be a crucial factor in patient stratification.